Our results indicate thatBRCA2mutations have no significant effect on the survival of Chinese women with HR-positive/HER2-negative breast cancer.doi:10.1177/17588359241242613Pu-Chun LiYi-Fan ZhuJia-Ni PanQiao-Yan ZhuYu-Yang LiaoXiao-Wen Ding...
[15]Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.2024 ASCO 1006 [16] Bardia, Aditya et al. ...
HER2高表达水平高(IHC 3+ 或 2+/ISH+)的患者被归类为 HER2 阳性,可用 HER2 靶向疗法治疗,约占所有乳腺癌的 15-20%[10]。从历史上看,未被归类为 HER2 阳性的肿瘤被归类为 HER2 阴性;然而,这些肿瘤中的许多仍然带有一定程度的 HER2 表达[11]。据估计,大约 60-65% 的 HR 阳性、HER2 阴性乳腺癌为 HER2...
基于这一结果,证实了T-DXd在至少一线标准内分泌治疗进展的HR+/HER2低表达和HER2超低表达患者中优异疗效。研究结果进一步支持了T-DXd作为HR+/HER2低表达患者内分泌治疗进展后的治疗选择的同时,也进一步细分出了HER2超低表达患者,并提示了对于这部分患者带来的获益。T-DXd再次拓展了抗HER2治疗的边界,持续拓宽着在HER2...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding pre...
Sacituzumab govitecan(Trodelvy) is a monoclonal antibody with an attached chemotherapy drug. It is used to treat some advanced HR+, HER2-negative breast cancer. Learn more abouthormone therapy to treat breast cancer.
Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;852748.Lin M, et al. Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. J Cancer....
Expert nurse practitioner and physician associate faculty will discuss the latest advances and potential with the CDK4/6 inhibitors for HR-positive/HER2-negative breast cancer care.AAPA | ANCC Who Should Attend This program is intended for nurse practitioners, physician associates, clinical nurse ...
英文标题:Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study. ...
DESTINY-Breast04 III期关键性试验达到阳性结果:与医生选择的化疗方案相比,无论激素受体 (HR) 状态,Enhertu(trastuzumab deruxtecan,简称T-DXd)在 HER2低表达不可切除和/或转移性乳腺癌患者的无进展生存期(PFS)和总生存期(OS)方面表现...